HC Wainwright Issues Positive Estimate for Agenus Earnings

Agenus Inc. (NASDAQ:AGEN) – HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for shares of Agenus in a research note issued on Tuesday, March 18th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings of ($1.85) per share for the quarter, up from their previous estimate of ($2.29). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($4.37) EPS, FY2026 earnings at ($3.79) EPS, FY2027 earnings at ($3.25) EPS, FY2028 earnings at ($3.48) EPS and FY2029 earnings at ($2.32) EPS.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, beating analysts’ consensus estimates of ($2.36) by $0.32. The company had revenue of $26.84 million during the quarter, compared to the consensus estimate of $30.09 million.

Separately, Robert W. Baird reduced their price target on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.75.

Agenus Stock Performance

Shares of AGEN opened at $1.67 on Thursday. The stock has a 50 day simple moving average of $3.04 and a 200 day simple moving average of $3.70. Agenus has a 52-week low of $1.64 and a 52-week high of $19.69. The firm has a market capitalization of $39.18 million, a PE ratio of -0.15 and a beta of 1.23.

Institutional Investors Weigh In On Agenus

A number of institutional investors and hedge funds have recently made changes to their positions in AGEN. Corton Capital Inc. bought a new stake in Agenus in the 4th quarter valued at $36,000. Virtu Financial LLC acquired a new stake in shares of Agenus during the fourth quarter worth $51,000. Apollon Wealth Management LLC acquired a new stake in shares of Agenus during the fourth quarter worth $55,000. EP Wealth Advisors LLC bought a new position in shares of Agenus in the third quarter worth $55,000. Finally, Bank of Montreal Can bought a new position in shares of Agenus in the fourth quarter worth $69,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.